The average of price targets set by Wall Street analysts indicates a potential upside of 84.5% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, ...
Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...
Hosted on MSN4d
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON ...
Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM. Type ...
Beam Therapeutics (BEAM – Research Report) received a Buy rating and a $37.00 price target from Bernstein analyst William Pickering today. The ...
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 ...
Combining microbeam radiotherapy with targeted radiosensitizers could treat tumours while sparing normal brain tissues ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
United Healthcare Insurance Co. struck a deal to resolve three proposed class actions saying it wrongly refused to cover a ...
Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve ...
Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback